PAK4 and cancer: By showing also a competitive advantage conferred by PAK4 to established breast cancer cells, acting through the noncanonical NF-κB signaling subunit RELB to prevent senescence-like growth arrest, we reveal a selective vulnerability of cancer cells to PAK4 inhibition that may be explored as a therapeutic strategy.